Sugemalimab
Sugemalimab is a fully human monoclonal IgG4 antibody targeting programmed death ligand 1 (PD-L1), used as an immune checkpoint inhibitor for the treatment of non-small cell lung cancer and classical Hodgkin lymphoma. By blocking the PD-1/PD-L1 inhibitory axis, it restores T-cell antitumor immune responses that are suppressed by PD-L1 expression on tumor cells and the tumor microenvironment. It has demonstrated improved progression-free and overall survival in combination with chemotherapy.
Terapötik Alanlar
Etki Mekanizması
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Sugemalimab is a fully human monoclonal IgG4 antibody targeting programmed death ligand 1 (PD-L1), used as an immune checkpoint inhibitor for the treatment of non-small cell lung cancer and classical Hodgkin lymphoma. By blocking the PD-1/PD-L1 inhibitory axis, it restores T-cell antitumor immune responses that are suppressed by PD-L1 expression on tumor cells and the tumor microenvironment. It has demonstrated improved progression-free and overall survival in combination with chemotherapy.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Sugemalimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594535. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sugemalimab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sugemalimab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sugemalimab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sugemalimab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sugemalimab"></drugfyi-drug>